$PHAT
Phathom Pharmaceuticals, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020024514 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.510M $800.0K
YoY Change 463.75%
% of Gross Profit
Research & Development $15.87M $429.0K
YoY Change 3598.14%
% of Gross Profit
Depreciation & Amortization $52.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $20.38M $1.226M
YoY Change 1561.91% 388.45%
Operating Profit -$20.38M -$1.226M
YoY Change 1561.91% 388.45%
Interest Expense $738.0K $11.00K
YoY Change 6609.09%
% of Operating Profit
Other Income/Expense, Net $234.0K -$25.00K
YoY Change -1036.0% 733.33%
Pretax Income -$20.14M -$1.250M
YoY Change 1511.2%
Income Tax
% Of Pretax Income
Net Earnings -$20.14M -$1.251M
YoY Change 1509.99% 392.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$800.8K -$48.30K
COMMON SHARES
Basic Shares Outstanding 28.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $256.7M
YoY Change
Cash & Equivalents $256.7M $72.00K
Short-Term Investments
Other Short-Term Assets $5.200M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $261.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.700M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K
YoY Change
Total Long-Term Assets $2.100M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $261.8M
Total Long-Term Assets $2.100M
Total Assets $263.9M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M
YoY Change
Accrued Expenses $3.400M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.576M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $45.90M
YoY Change
Other Long-Term Liabilities $4.125M
YoY Change
Total Long-Term Liabilities $4.125M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.576M
Total Long-Term Liabilities $4.125M
Total Liabilities $55.22M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$276.6M
YoY Change
Common Stock $485.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $208.7M -$2.537M
YoY Change
Total Liabilities & Shareholders Equity $263.9M
YoY Change

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$20.14M -$1.251M
YoY Change 1509.99% 392.52%
Depreciation, Depletion And Amortization $52.00K $0.00
YoY Change
Cash From Operating Activities -$11.42M -$807.0K
YoY Change 1314.75%
INVESTING ACTIVITIES
Capital Expenditures $676.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$676.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.00M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -11.42M -807.0K
Cash From Investing Activities -676.0K 0.000
Cash From Financing Activities 25.00M 0.000
Net Change In Cash 12.91M -807.0K
YoY Change -1699.38%
FREE CASH FLOW
Cash From Operating Activities -$11.42M -$807.0K
Capital Expenditures $676.0K $0.00
Free Cash Flow -$12.09M -$807.0K
YoY Change 1398.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4125000
CY2020Q1 us-gaap Liabilities
Liabilities
55220000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
485253000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
484372000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
148000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
22777000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
606000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-276560000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256419000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
208695000
CY2019Q1 us-gaap Interest Expense
InterestExpense
11000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
797000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20375000
CY2020Q1 us-gaap Long Term Debt
LongTermDebt
45913000
CY2019Q4 phat Warrant Liability Current
WarrantLiabilityCurrent
413000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4576000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
1226000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15865000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25153553
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4510000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1226000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
878000
CY2019Q1 phat Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-14000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1251000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6585503
CY2019Q1 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
0
CY2019Q1 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
-29000
CY2019Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
11000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-2537000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
227955000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263915000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
257178000
CY2020Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
112000
CY2019Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
200000
CY2020Q1 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
177000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28964506
CY2020Q1 phat Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
CY2019Q1 phat Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
14000
CY2020Q1 phat Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity
AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
318000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
563000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1286000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-20141000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-1251000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
563000
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
199000
CY2019Q1 phat Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
14000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6680000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
120000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1492000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
539000
CY2020Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
81000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
20375000
CY2020Q1 us-gaap Interest Expense
InterestExpense
738000
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-95000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
234000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-20141000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32470402
CY2020Q1 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
404000
CY2020Q1 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
43000
CY2020Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2019Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
11000
CY2020Q1 phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
-48000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
200000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11417000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-807000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
676000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-676000
CY2020Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12907000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-807000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
243765000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
879000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
256672000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
458000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
CY2020Q1 phat Non Cash Final Interest Payment Fee
NonCashFinalInterestPaymentFee
2063000
CY2020Q1 phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
CY2019Q1 phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
-114000
CY2020Q1 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
289000
CY2019Q1 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
46000
CY2020Q1 phat Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
0
CY2019Q1 phat Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
11000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P0Y
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p>
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30874000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22273000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9000000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M21D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2019Q4 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
2.168-for-1
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2.168
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
828000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
471000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8000
CY2020Q1 us-gaap Depreciation
Depreciation
52000
CY2019Q1 us-gaap Depreciation
Depreciation
0
CY2020Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020Q1 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1985000
CY2019Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
384000
CY2020Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
641000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1052000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
370000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
478000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
405000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
754000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
796000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
110000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
171000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
176000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
181000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
186000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
80000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
904000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
150000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y29D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2020Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4087000
CY2020Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear
2457000
CY2020Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
13218000
CY2020Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
19065000
CY2020Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
17840000
CY2020Q1 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive
11198000
CY2020Q1 phat Long Term Debt And Interest
LongTermDebtAndInterest
63778000
CY2020Q1 phat Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
13778000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4236248
CY2020Q1 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
425295
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3810953
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13423199
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1400528
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
134227
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1534755
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.10
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.39
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.31
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M8D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M23D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6263
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0119
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
563000

Files In Submission

Name View Source Status
0001564590-20-024514-index-headers.html Edgar Link pending
0001564590-20-024514-index.html Edgar Link pending
0001564590-20-024514.txt Edgar Link pending
0001564590-20-024514-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
phat-10q_20200331.htm Edgar Link pending
phat-20200331.xml Edgar Link completed
phat-20200331.xsd Edgar Link pending
phat-20200331_cal.xml Edgar Link unprocessable
phat-20200331_def.xml Edgar Link unprocessable
phat-20200331_lab.xml Edgar Link unprocessable
phat-20200331_pre.xml Edgar Link unprocessable
phat-ex101_133.htm Edgar Link pending
phat-ex102_134.htm Edgar Link pending
phat-ex311_6.htm Edgar Link pending
phat-ex312_7.htm Edgar Link pending
phat-ex321_9.htm Edgar Link pending
phat-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending